Sagawa Takaomi, Kogiso Tomomi, Sugiyama Hisashi, Hashimoto Etsuko, Yamamoto Masakazu, Tokushige Katsutoshi
Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Pediatric Cardiology and Adult Congenital Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Hepatol Res. 2020 Jul;50(7):853-862. doi: 10.1111/hepr.13500. Epub 2020 Apr 30.
Hepatocellular carcinoma (HCC) can arise from Fontan-associated liver disease (FALD); this is known as FALD-HCC. The clinical features of FALD-HCC are unclear. Thus, we examined the incidence and clinical characteristics of FALD-HCC.
From 1972 to 2019, 122 patients developed liver disease after undergoing Fontan procedures. HCC was diagnosed in 12 (9.8%) FALD patients. We compared FALD-HCC and non-HCC patients.
The incidence of HCC was 0.8% and 2.9% in FALD 10 and 20 years after the Fontan procedure, respectively. The median age of patients at diagnosis of HCC was 32.5 years (range 20.6-46.1 years), and seven of the 12 patients were men. Patients with FALD-HCC had a higher incidence of liver cirrhosis and polysplenia than non-HCC patients. Liver tumors were detected as single nodules in eight patients, and the median diameter was 47 mm (range 11-105 mm). HCC was treated by surgical resection in two patients, transcatheter arterial chemoembolization or chemotherapy in three patients, and proton beam therapy in four patients. Three patients could not be treated because of their poor condition. Four patients died of liver/cardiac failure and HCC, and HCC was controlled in three patients. The survival rate after 25 years was significantly lower in patients with FALD-HCC than non-HCC patients (68.6% vs. 97.9%, respectively; P < 0.01).
Of the 122 patients with FALD, 12 developed HCC 20 years after surgery. Because complications of HCC are associated with poor prognosis, constant surveillance for HCC should begin 10 years after surgery.
肝细胞癌(HCC)可源于与Fontan相关的肝病(FALD);这被称为FALD-HCC。FALD-HCC的临床特征尚不清楚。因此,我们研究了FALD-HCC的发病率和临床特征。
1972年至2019年,122例患者在接受Fontan手术后出现肝病。12例(9.8%)FALD患者被诊断为HCC。我们比较了FALD-HCC患者和非HCC患者。
Fontan手术后10年和20年,FALD患者中HCC的发病率分别为0.8%和2.9%。诊断为HCC的患者中位年龄为32.5岁(范围20.6-46.1岁),12例患者中有7例为男性。FALD-HCC患者肝硬化和多脾的发生率高于非HCC患者。8例患者的肝脏肿瘤被检测为单个结节,中位直径为47mm(范围11-105mm)。2例患者接受了手术切除治疗HCC,3例患者接受了经动脉化疗栓塞或化疗,4例患者接受了质子束治疗。3例患者因病情不佳无法接受治疗。4例患者死于肝/心功能衰竭和HCC,3例患者的HCC得到控制。FALD-HCC患者25年后的生存率显著低于非HCC患者(分别为68.6%和97.9%;P<0.01)。
在122例FALD患者中,12例在手术后20年发生了HCC。由于HCC的并发症与预后不良相关,术后10年应开始对HCC进行持续监测。